Home › Targets › ADRA2C
Radioligand therapy target profile

ADRA2C: IHC Expression in Cancer and Radioligand Target Profile

adrenoceptor alpha 2C · Ensembl ENSG00000184160 · Data updated 2026-11-01

ADRA2C, adrenoceptor alpha 2C, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, ADRA2C staining is highest in cervical cancer (50% of samples positive), liver cancer (42% of samples positive) and skin cancer (25% of samples positive). Evidence on whether ADRA2C internalizes is mixed. Clinical status: FDA-approved drug (any modality).

Is ADRA2C the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze ADRA2C free
LocalizationCell-Surface
Top cancer (IHC)Cervical Cancer
InternalizationUncertain
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.64

Is ADRA2C a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

ADRA2C IHC staining by cancer type

Protein expression of ADRA2C across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Cervical Cancer0.28Medium50%
Liver Cancer0.17Low42%
Skin Cancer0.08Low25%
Colorectal Cancer0.08Low25%
Thyroid Cancer0.08Low25%
Bladder Cancer0.04Low13%
Kidney Cancer0.03Low10%
Breast Cancer0.03Low8%
Melanoma0.03Low8%
Gastric Cancer0.03Low8%
Endometrial Cancer0.03Low8%

Not detected by IHC in: head and neck cancer, ovarian cancer, lymphoma, neuroendocrine tumors, lung cancer, pancreatic cancer, prostate cancer, testicular cancer, glioma.

Is ADRA2C internalized?

Uncertain. The abstract discusses genetic polymorphisms and their association with ventricular fibrillation but does not provide clear evidence of ADRA2C undergoing internalization or endocytosis upon ligand or antibody binding.

Sources: PMID 36926933. AI-extracted from abstracts, so verify before citing.

ADRA2C clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for ADRA2C yet. Search ClinicalTrials.gov for ADRA2C trials.

ADRA2C normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ADRA2C in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

ADRA2C gene essentiality (DepMap)

CRISPR knockout effect across 1250 cancer cell lines: 0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related cervical cancer radioligand targets

EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · CEA (CEACAM5) · Mesothelin (MSLN) · ITGB6 · ITGAV

See all radioligand therapy targets in cervical cancer.

See how ADRA2C ranks against 15,000 targets for your indication.

Analyze ADRA2C free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is ADRA2C the right target for your program? · 5 free analyses, no card Analyze ADRA2C free